Yes. Organizations may use the same clinical quality measure for each program if the measure is relevant to each program's population. Each program's population must be measured separately.
FAQ Directory
Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can ask a question through My NCQA.
Filter Results
- Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
- Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
- Print
Print this page.
Print this page.
5.15.2012 Clinical quality measures across programs May organizations use the same clinical quality measure for each program brought forward for accreditation?
5.15.2012 Collecting feedback from program participants Is an organization required to collect feedback from all programs and all program participants, or may the organization choose from whom to collect feedback?
Organizations must include all programs or population segments to assess for WHP 9, Element A.
Data collection must be across all programs and include eligible participants. If an organization uses a sample, the sample must be randomized to give all eligible participants an equal chance of being included.
4.16.2012 Use of Imaging Studies for Low Back Pain (LBP) In the November 2011 release of the MY2011 P4P Manual, the table LBP-D contains an invalid CPT code, 72011. Is this an error?
4.16.2012 Meaningful Use of Health Information Technology (MUHIT) In the November 2011 release of the MY2011 P4P Manual, the examples for scoring of the MUHIT domain in the Description and Domain Structure sections (pp 114 and 115) seem to have incorrect calculations. Is this an error?
Yes. The example on page 114 should read as follows:
100 out of 100 PCPs meet the criteria = 100%
_ 5 points for certified and 3.75 for non-certified
25 of 100 certified = ((25% * 5) = 1.25)
75 of 100 non-certified = ((75% * 3.75) = 2.81)
Total points = ((1.25+ 2.81) = 4.06)
The example on page 115, in the Point allocation for POs using ONC-ATCB certified software section, should read as follows:
For example, if a PO earned 60 points, its overall calculated P4P score would be 18. Scores are rounded to the nearest whole number.
These errors will be corrected in the September 2012 release of the MY 2012 manual.
4.16.2012 Proportion of Days Covered by Medications (PDC) The Eligible Population criteria state that continuous enrollment for PDC is the index prescription date (IPD) through the end of the measurement year or until death or disenrollment, and that there is no allowable gap. Are members with two separate enrollment periods that meet the 90 day requirement excluded because of the gap in enrollment, or are they counted as two separate measurement periods?
3.16.2012 Breast Cancer Screening (BCS) On the Clinical Measure file layout the BCS measure is listed as Breast Cancer Screening: Ages 52-69 but the measure description indicates that it is for ages 50 _ 69. Is there an error in the Clinical Measure file layout?
3.16.2012 Proportion of Days Covered by Medications (PDC) In the November 2011 release of the MY2011 P4P specifications, the wording under Definitions and Eligible Population is confusing. The definition of the Index Prescription Date (IPD) states that the index date should occur at least 91 days before the end of the measurement period, but under Continuous Enrollment, the manual states that the IPD must occur at least 91 days prior to the end of the measurement year. Should we be looking back from the end of the measurement period or the end of the measurement year?
The Index Prescription Date (IPD) should occur at least 91 days before the end of the measurement period, as stated in the definition of IPD. The Continuous Enrollment section should refer to the measurement period, for both self-reporting POs and for health plans.
This error will be corrected in the September 2012 release of the MY 2012 manual.
3.16.2012 Asthma Medication Ratio (AMR) In the November 2011 release of the MY 2011 P4P specifications, Table AMR-C: Asthma Medications does not match exactly with Table ASM-C in the 2012 HEDIS volume. Is this an error?
3.16.2012 Asthma Medication Ratio (AMR) Based on the MY 2010 P4P Crosswalk to HEDIS 2011 NDC List document, P4P Table AMR-C crosswalks to the HEDIS table ASM-C for the NDC list, but long-acting inhaled beta-2 agonists are no longer included in Table AMR-C. Should they be used in the Asthma Medication Ratio measure for P4P?
3.16.2012 Diabetes Care (CDC) In the November 2011 release of the MY 2011 P4P specifications, Table CDC-A: Prescriptions to Identify Members With Diabetes does not match exactly with Table CDC-A in the 2012 HEDIS volume. Is this an error?
3.16.2012 Avoidance of Antibiotic Treatment for Adults With Acute Bronchitis (AAB) In the November 2011 release of the MY 2011 P4P specifications, Table AAB-E: Antibiotic Medications does not match exactly with Table AAB-D in the 2012 HEDIS volume. Is this an error?
There is an error in the manual. In Table AAB-E: Antibiotic Medications,
the first two rows, 5-aminosalicylates and Amebicides should not be in the table,
in the row Aminoglycosides the drug Neomycin should not be in the table,
in the row First generation cephalosporins, the drug Cephradine should not be in the table,
in the row Miscellaneous antibiotics the drug Vancomycin should be included in the table,
the row sulfamethoxazole-trimethoprim DS should not be in the table,
in the row natural penicillins the drug Penicillin G benzathine should be included in the table,
in the row Third generation cephalosporins, the drugs Cefditoren and Cefpodoxime should be included in the table,
in the row Third generation cephalosporins, the drug Cefoperazone should not be in the table.
These errors will be corrected in the September 2012 release of the MY 2012 manual.
3.16.2012 Annual Monitoring for Patients on Persistent Medications (MPM) In the November 2011 release of the MY 2011 P4P specifications, Table MPM-A: Drugs to Identify Members on ACE Inhibitors or ARBs does not match exactly with Table CDC-L in the 2012 HEDIS volume. Is this an error?
There is an error in the manual. In the Table MPM-A: Drugs to Identify Members on ACE Inhibitors or ARBs, in the row Antihypertensive combinations the drugs Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-hydrochlorothiazide-olmesartan and Amlodipine-telmisartan should be included in the table.
This error will be corrected in the September 2012 release of the MY 2012 manual.